FDA Aligns with NervGen Pharma on Phase 3 Registrational Study for NVG-291 in Chronic Tetraplegia
Summary
NervGen Pharma has announced a successful End-of-Phase 2 meeting with the FDA, securing alignment on the design of its RESTORE Phase 3 registrational study for NVG-291 in chronic tetraplegia. This is a critical de-risking event for the company's lead therapeutic candidate, moving it closer to potential market approval. The FDA's agreement on the study design, including the primary endpoint, provides a clear path forward for the pivotal trial. This positive clinical development is particularly significant given the company's recent 'going concern' warning from its auditor, highlighting the importance of pipeline progress for its long-term viability. Traders will be watching for the initiation of the Phase 3 study, which is expected in mid-2026, and subsequent data readouts as key catalysts.
At the time of this announcement, NGEN was trading at $4.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $349.4M. The 52-week trading range was $3.51 to $6.30. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.